Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab

International Journal of Hematology

Volumn 89, Issue 3, 2009, Pages 400-402

  Sonoki, Takashi ^a   Li, Yaqiong ^a   Miyanishi, Setsuko ^b   Nakamine, Hirokazu ^c   Hanaoka, Nobuyoshi ^a   Matsuoka, Hiroshi ^a   Mori, Ichiro ^a   Nakakuma, Hideki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Tenri Institute of Medical Research   (Japan)

^c KANSAI UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MESSENGER RNA; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; CYTOTOXICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; LETTER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINE; CELL SEPARATION; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CELL SEPARATION; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 67649199930     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0295-4     Document Type: Letter

References (8)

1. MR Smith 2003 Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 7359 68 10.1038/sj.onc.1206939
2. BD Cheson PL Leonard 2008 Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N Engl J Med 359 613 26 10.1056/NEJMra0708875
3. T Kinoshita H Nagai T Murate H Saito 1998 CD20 negative relapse in B-cell lymphoma after treatment with rituximab J Clin Oncol 16 3916
4. TA Davis DK Czerwinski R Levy 1999 Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin Cancer Res 5 611 5
5. T Alvaro-Naranjo J Jaen-Martinez J Guma-Pardro R Bosch-Princep MT Salvado-Usach 2003 CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of literature Ann Hematol 82 585 8 10.1007/s00277-003-0694-1 (Pubitemid 37220678)
6. A Tomita J Hiraga H Kiyoi M Ninomiya T Sugimoto M Ito 2007 Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy Int J Hematol 86 49 57 10.1532/IJH97.07028 (Pubitemid 47204490)
7. Y Terui T Sakurai Y Mishima 2005 Identification of CD20 mutations in malignant lymphoma: can they be predictors of response to rituximab? Blood 106 88a abstract
8. M Crescenzi M Seto GP Herzig PD Weiss RC Griffith SJ Korsmeyer 1988 Thermostable DNA polymerase chain amplification of t(14;18)(q32;q21) chromosome breakpoints and detection of minimal residual disease Proc Natl Acad Sci USA 85 4869 73 10.1073/pnas.85.13.4869